Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach  by Blanes, Margarita et al.
Biol Blood Marrow Transplant 19 (2013) 69e74American Society for Blood
ASBMT
and Marrow TransplantationIntravenous Busulfan and Melphalan as a Conditioning
Regimen for Autologous Stem Cell Transplantation in
Patients with Newly Diagnosed Multiple Myeloma: A
Matched Comparison to a Melphalan-Only Approach
Margarita Blanes 1,2, Juan J. Lahuerta 3, José D. González 4, Paz Ribas 5,
Carlos Solano 6, Adrían Alegre 7, Joan Bladé 8, Jesús F. San Miguel 9,
Miguel A. Sanz 1, Javier de la Rubia 1,10,*
1Hematology Service, University Hospital La Fe, Valencia, Spain
2 Program of Doctorate of Internal Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain
3Hematology Service, Hospital 12 de Octubre, Madrid, Spain
4Hematology Service, Hospital Insular de Canarias, Las Palmas, Spain
5Hematology Service, Hospital Dr. Peset, Valencia, Spain
6Hematology Service, Hospital Clínico, Valencia, Spain
7Hematology Service, Hospital Universitario de la Princesa, Madrid, Spain
8Hematology Service, Hospital Clínic, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
9Hematology Service, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain
10Universidad Católica de Valencia, Valencia, SpainArticle history:
Received 6 June 2012
Accepted 8 August 2012
Key Words:
Intravenous busulfan
Melphalan
Multiple myeloma
Autologous transplantationFinancial disclosure: See Acknowle
* Correspondence and reprint re
tology Service, 2 University Hosp
Valencia, Spain.
E-mail address: delarubia_jav.@
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Melphalan 200 mg/m2 (MEL200) is the standard conditioning regimen administered to newly diagnosed
patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT). Few alter-
natives have been explored in order to improve the antimyeloma activity of this conditioning. We compare i.v.
busulfan (BU) 9.6 mg/kg and MEL 140 mg/m2 (MEL140) versus MEL200 mg/m2 as a conditioning regimen
before ASCT for newly diagnosed patients with MM. For this purpose, 51 patients receiving i.v. BU plus MEL
were compared to 102 patients receiving MEL200 mg/m2 in a 1:2 matched control analysis. Matching criteria
included age, clinical stage at diagnosis, and response to induction therapy. No differences in the overall and
complete response (CR) rates were observed after ASCT between both groups. After a median follow-up of 63
and 50 months in control and BU plus MEL groups, progression-free survival (PFS) was 24 and 33 months,
respectively (P ¼ .10). Most frequent toxicities included mucositis and febrile neutropenia in both groups. No
case of sinusoidal obstruction syndrome was observed. Transplant-related mortality was 4% and 2% in BU plus
MEL and control groups, respectively. ASCT conditioned with i.v. BU plus MEL may be considered an effective
and well-tolerated alternative to a MEL-only approach as a conditioning regimen for patients with MM who
are candidates for ASCT. (Clinicaltrials.gov identiﬁer: NCT00560053 and NCT00804947.)
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous stem cell transplantation (ASCT) is considered
the standard of care for patients younger than 65 years with
newly diagnosed multiple myeloma (MM) [1-5], based on
the results of a randomized trial of the Intergroup Franco-
phone du Myeloma [6], showing that melphalan 200 mg/m2
(MEL200) was superior toMEL140 plus total body irradiation
(TBI). In spite of the theoretical clinical relevance of the
conditioning regimen, progress in this area is relativelyscarce.
Moreover, most of the alternative preparative regimens
that so far have been investigated did not show convincing
evidence of superiority overMEL200 [7-16]. Nevertheless, the
interest in the ﬁeld may be renewed with the availability of
novel antimyeloma effects.
Results of 2 retrospective studies conducted by the
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12.08.009Español de Mieloma (PETHEMA/GEM) study groups showed
encouraging results in terms of response rate and progres-
sion-free survival (PFS)with the combination of oral busulfan
(BU) and MEL compared with MEL200 or MEL140 mg/m2
(MEL140) plus TBI [17,18]. Based on these results, PETHEMA/
GEM launched a prospective trial (PETHEMA/GEM2000)
aimed to investigate the combination of oral BU and MEL
(BUMEL) as a conditioning regimen in patients with newly
diagnosed MM. The ﬁrst interim analysis of this trial showed
a higher than expected hepatic toxicity, particularly sinu-
soidal occlusive syndrome (SOS) [19], and the protocol was
amended so that MEL200 became the preparative regimen.
However, and despite this complication, ﬁnal results of this
studywith a longer follow-up showed that conditioningwith
BUMEL was associated with a longer PFS than that observed
with MEL200 [20].
Taking advantage of the availability of an i.v. formulation
of BU, we conducted a phase II, prospective, multicenter trial
of i.v. BUMEL as a preparative regimen in a series of 55
patients with MM undergoing ASCT either as front-line
therapy or after relapse from a previous transplantation. Our
results showed that BUMEL was associated with a high
response-rate and a low transplant-related mortality [21].Transplantation.
M. Blanes et al. / Biol Blood Marrow Transplant 19 (2013) 69e7470Based on these encouraging results, we have now performed
a matched case-control analysis to compare the outcome of
patients with MM undergoing front-line therapy and a single
ASCT after i.v. BUMEL or MEL200 as a preparative regimen.
MATERIALS AND METHODS
BUMEL Group
Between June 2005 and September 2009, a series of 51 consecutive
patients with newly diagnosed MM from 5 institutions participating in the
BUMEL phase II trial were included in the study [21]. Induction therapy
consistedof6 cycles of vincristine, carmustine,melphalan, cyclophosphamide,
and prednisone (VBMCP), alternating with vincristine, carmustine, adria-
mycin, and dexamethasone (VBAD) or vincristine, adriamycin, and dexa-
methasone followed by ASCT prepared with i.v. BUMEL.
Control Group
For comparison, 102 pair mates were selected as the control group
among patients who entered the GEM2000 study in a 2:1 ratio. The
GEM2000 protocol was active from January 2000 to February 2005. For
patients included in this study, induction therapy was similar to that
administered to the BUMEL group of patients, but this was followed by ASCT
preparedwithMEL200. Patients failing to achieve complete response (CR) or
near CR (nCR) after ASCT were offered as a second autologous trans-
plantation [22e26].
Matched Control Study Details
Casematchingwasperformedaccording toage, clinical stage at diagnosis
(Durie-Salmon and International Staging System), and response to induction
therapy. To ensure a homogeneous selection of patients in the control group,
and in order to minimize the risk of bias (selecting an unusual proportion of
CR/nCR after transplantation in this group), those patients receiving 2
autologous transplantations were potentially eligible during the match
process.
In both studies, informed consent was provided according to the
Declaration of Helsinki. The GEM2000 protocol and BUMEL clinical trial
were registered at ClinicalTrials.gov as NCT00560053 and NCT00804947,
respectively.
Autologous Transplantation
The BUMEL conditioning regimen consisted of BU at a dose of 3.2 mg/kg
administered i.v. over 3 hours once a day on days5 to3 (total dose 9.6mg/
kg), followedbyMELatadoseof140mg/m2onday2.Patients included in the
controlgroupunderwentASCTafterbeingconditionedwithMEL200mg/m2 in
a single dose onday2 or in 2 divided doses ondays3 and2. As it has been
previously mentioned, patients failing to achieve at least nCR were offered
a second autologous transplantation. The preparative regimen in this second
transplantation was either MEL200 or a combination of cyclophosphamide
(1.5mg/m2/d, days6 to3), carmustine (300mg/m2, day6), and etoposide
(125 mg/m2/12 h, days 6 to 4). The minimum threshold dose of CD34 þ
cells to be collected in the control group was 4  106 per kilogram of body
weight, and theminimumnumber of CD34þ cells to undergo transplantation
in the BUMEL group was 2  106 per kilogram of body weight. All patients
received standard supportive care measures, including growth factor support,
blood transfusions, and prophylactic or therapeutic antibiotics according to
local departmental guidelines at the time. In addition, every patient in the
BUMEL group received oral phenytoin for seizure prophylaxis. Finally, main-
tenance treatment with a-interferon and steroids was given in 65 patients
(64%) in the control group, whereas 33 of the 51 patients (65%) in the BUMEL
group received maintenance that consisted of a-interferon and steroids (29
patients) or immunomodulatory agents (4 patients).
Deﬁnitions
Disease status at transplantation and the response to ASCT was evalu-
ated according to the European Group for Blood and Marrow Trans-
plantation criteria, but an nCR category, as deﬁned by disappearance of
monoclonal protein at routine electrophoresis but positive immunoﬁxation,
was added to European Group for Blood and Marrow Transplantation
criteria [2,27]. Responses were assessed at the time of enrollment (after
induction therapy) and 3 months after ASCT. Toxicities were graded
according to criteria reported by Bearman et al. [28]. Duration of hospital-
ization was measured from the day of transplantation to the day of
discharge, and any death unrelated to relapse or disease progression during
the ﬁrst 100 days was considered an event for transplant-related mortality.
Statistical Analysis
The primary objective of this study was to compare the overall response
and CR/nCR rate 3 months after ASCT. Secondary endpoints were safetyproﬁle of the conditioning regimens, PFS, time to progression (TTP), and
overall survival (OS). The proportions of patients with a given set of char-
acteristics were compared by the chi-square test or by the Fisher exact test.
Differences in the means of continuous measurements were tested by the t
test and checked by the Mann-Whitney U test. The duration of PFS was
calculated for all patients from the day of transplantation to the TTP, relapse,
death from any cause, or reference date. TTP was estimated from the day of
transplantation to the date of relapse or disease progression and OS from the
day of transplantation to the date of death or the last visit. PFS, TTP, and OS
were plotted according to the Kaplan-Meier product-limit method with
comparisons made by the log-rank test. All patients were followed until
death or reference date (March 31, 2012). All statistical analyses were per-
formed with BMDP software (BMDP, University of California, Berkeley, CA).RESULTS
Patient Characteristics
A summary of patient characteristics and laboratory
parameters are given in Table 1. As per protocol, patients in
both groups had similar disease characteristics at diagnosis
and comparable response status before transplantation.
VBMCP/VBADchemotherapywas administered to42patients
(82%) and 99 patients (97%) in the BUMEL and control groups,
respectively. Median time between diagnosis and trans-
plantation was 9.2 months (range, 5-13.1 months) and 9.4
(range, 4.2-14.7 months) in the BUMEL and control groups,
respectively. Finally, in the control group, andaccording to the
protocol design, 19 patients who did not achieve CR with this
ﬁrst transplantation underwent a second transplantation
within 8 months after the ﬁrst ASCT.Engraftment and Transplant-related Complications
The hematopoietic reconstitution was similar in the 2
groups. The median time to reach a neutrophil count
0.5  109/L was 11 days in both groups. The median time to
reach a platelet count greater than 20  109/L was 13 days in
the BUMEL group and 12 days in the control group (Table 2).
Regimen-related toxicities are detailed in Table 2. Muco-
sitis was the nonhematologic toxicity most frequently
observed in both groups (45 and 47 patients in the BUMEL
and control group, respectively) followed by febrile neu-
tropenia, 43 patients (16 bacteremias) in the BUMEL and 62
patients (24 bacteremias) in the control group. Hepatic
toxicity was not reported in the control group, whereas mild
(grade I/II) liver toxicity was observed in 7 patients (14%)
among BUMEL recipients, although no patient developed
SOS. Other toxicities observed during the early post-
transplantation period are shown in Table 2. Overall, the
median duration of hospitalizationwas 21 and 17 days in the
BUMEL and control group, respectively (P ¼ .04) (Table 2).
Finally, there were 2 (4%) treatment-related deaths in the
BUMEL group and 2 (2%) in the control group. Three of the
4 patients died because of infectious complications, and the
remaining patient died due to a sudden cardiac arrest
22 days after transplantation (Table 2).Response after ASCT
The response rate after ASCT is shown in Table 3. No
differences in the overall response and in the CR/nCR were
observed between both groups of patients. The overall
response ratewas90%and91% in theBUMELand in the control
group, respectively. Twenty-three patients (45%) improved
their response after transplantation in the BUMEL group, with
26 patients (51%) achieving either CR (23.5%) or nCR (27.5%)
and20(39%)hadapartial response (PR),whereas in the control
group, 34 patients (33%) achieved CR, 16 patients (16%) ach-
ieved nCR, and 43 patients (42%) had a PR.
Table 2
Engraftment and Transplant-Related Toxicities According to Treatment
Group
Characteristic BUMEL group
(n ¼ 51)
Control group
(n ¼ 102)
P value
PMN>0.5  109/L, days
(range)
11 (9-33) 11 (7-22)
Platelet >20  109/L,
days (range)
13 (9-64) 12 (6-63)
Hospitalization, days
(range)
21 (12-42) 17 (11-41) .04
Febrile neutropenia 43 (84) 62 (61)
Fever of unknown
origin
19 (37) 24 (23.5)
MDI/bacteremia 16 (31)/16 (31) 28 (27)/24 (23.5)
CDI 8 (16) 10 (10)
Mucositis 45 (88) 47 (46) .0001
Grade I/II 10/35 14/33
Gastrointestinal 8 (16) 13 (13)
Grade I/II 5/3 6/7
Hepatic 7 (14) .004
Grade I/II 3/4 e
Other* 1 (2) 5 (5)
Grade I/II -/1 2/3
Transplant-related
mortality
2 (4)y 2 (2)z
BUMEL indicates busulfan and melphalan; PMN, neutrophil; MDI, micro-
biological documented infection; CDI, clinically documented infection.
Values are number (%) of patients.
* BUMEL group: cardiac toxicity, 1 patient. Control group: cardiac toxicity,
2 patients; renal toxicity, 1 patient; pulmonary toxicity, 1 patient; central
nervous system toxicity, 1 patient.
y Pneumonia and septic shock by Klebsiella pneumoniae (1 patient) and
septic shock by Acinetobacter spp (1 patient).
z Septic shock (1 patient) and sudden cardiac arrest (1 patient).
Table 3
Response before and after ASCT
BUMEL group (n ¼ 51) Control group (n ¼ 102)
Before ASCT After ASCT Before ASCT After ASCT
CR 4 (8) 12 (23.5) 8 (8) 34 (33)
nCR 6 (12) 14 (27.5) 12 (12) 16 (16)
PR 32 (62) 20 (39) 66 (64) 43 (42)
MR 5 (10) 2 (4) 8 (8) 3 (3)
SD 3 (6) 0 6 (6) 1 (1)
PD 1 (2) 1 (2) 2 (2) 3 (3)
BUMEL indicates busulfan and melphalan; ASCT, autologous stem cell
transplant; CR, complete response; nCR, near complete response; PR, partial
response; MR, minimum response; SD, stable disease; PD, progressive
disease.
Values are number (%) of patients.
Table 1
Characteristics of Patients According to Treatment Group
Characteristic BUMEL group
(n ¼ 51)
Control group
(n ¼ 102)
No. of Patients % No. of Patients %
Sex
Male 31 61 52 51
Female 20 39 50 49
Age (years) 61 (47-70) 61 (40-71)
Durie-Salmon stage
II 22 43 43 42
III 29 57 59 58
ISS stage
I 15 29 28 27
II 25 49 54 53
III 11 22 20 20
Isotype
IgG 27 53 59 58
IgA 10 19 24 23
Light chain 8 16 17 17
Other* 6 12 2 2
Hemoglobin (g/dL) 10.9 (4.9-15) 10.8 (4-15)
Serum creatinine (mg/dL) 1 (0.54-8.8) 1 (0.4-9)
b-2 microglobulin (mg/L) 3.6 (1.3-17.6) 3.2 (0.5-24.2)
Chemotherapy before ASCT
VBMCP/VBAD 42 82 99 97
VAD 9 18 3 3
Interval Dx-ASCT (months) 9.2 (5.1-13.1) 9.4 (4.2-14.7)
Year of ASCT 2005-2009 2001-2005
BUMEL indicates busulfan and melphalan; ISS, International Staging
System; ASCT, autologous stem cell transplant; VBMCP, vincristine, car-
mustine, melphalan, cyclophosphamide, and prednisone; VBAD, vincristine,
carmustine, adriamycin, and dexamethasone; VAD, vincristine, adriamycin,
and dexamethasone; Dx, diagnosis.
Note: No statistically signiﬁcant differences were found between the 2
treatment groups.
* BUMEL group: IgD (2patients); IgM (1patient); nonsecretory (3 patients);
Control group: nonsecretory (2 patients).
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PFS
After a median follow-up of 50 and 63 months, 30
patients had relapsed in the BUMEL group and 82 patients in
the control group with a median PFS of 33 months for those
who received BUMEL and 24 months for patients in the
control group. The 6-year PFS was 23% (95% CI, 14% to 32%) in
the BUMEL group compared to 17% (95% CI, 13% to 21%) in the
control group (P ¼ 0.1; Figure 1). Finally, when the 19
patients undergoing tandem transplantation in the control
group were excluded, the corresponding ﬁgures of PFS were
23% (95% CI, 14% to 32%) and 17% (95% CI, 13% to 21%) in the
BUMEL and control groups, respectively (P ¼ .15).
TTP
Median TTP was 37 months (95% CI, 31% to 43%) and 26
months (95% CI, 23% to 29%) in BUMEL and MEL200,
respectively (P ¼ .10; Figure 2).
OS
At the time of this analysis, 24 patients (47%) have died in
the BUMEL group. Twenty-one were myeloma-related
deaths, 2 patients died because of transplant-related
mortality, and the remaining patient died because of an acute
myocardial infarction 56 months after transplantation.
Overall, 62 patients (61%) have died in the control group: 53
because of relapse or progression and 5 because of trans-
plant-related complications (2 patients died after the ﬁrst
transplantation and 3 after the second transplantation), and
4 patients died while in response between 16 and 55 monthsafter transplantation because of septic shock (1 patient),
acute myocardial infarction (1 patient), and of unknown
cause in the remaining 2 patients. The median OS was 65.5
months for patients receiving BUMEL and 63 months for
those in the control group (P ¼ .86; Figure 3).
DISCUSSION
In the present study, we compared the clinical outcomes
of a series of 51 patients with newly diagnosed MM who
underwent transplantation after BUMEL conditioning to that
of double the number of matched patients who received
MEL200 only. Our results show a similar overall response and
CR/nCR rate in both groups of patients. PFS and TTP was,
however, longer among patients receiving BUMEL when
compared with those receiving a MEL-only conditioning
(33 versus 24 months and 37 versus 26 months, respec-
tively), with a PFS at 6 years of 23% and 17% in the BUMEL and
control group, respectively.
Figure 1. Progression free survival in BUMEL group (d) and control group ($$$).
M. Blanes et al. / Biol Blood Marrow Transplant 19 (2013) 69e7472Appreciating the difﬁculty of drawing ﬁrm conclusions
from historic controls, an effort was undertaken to account
for differences in relevant prognostic features by matching
patients closely for age, clinical stage, and response to
induction therapy. The primary endpoint of the study was to
compare overall response and CR/nCR rate in both groups of
patients. Our results show a similar overall response and CR/
nCR rate with BUMEL (90% and 51%) to that observed with
MEL200 (91% and 49%). Furthermore, CR/nCR in the BUMEL
group mirrored the previous PETHEMA/GEM experience,
conﬁrming the i.v. formulation of BU as having similar clin-
ical efﬁcacy than the oral one 19].
Notwithstanding the similar response rate, TTP (37 versus
26 months) and PFS (33 versus 24 months) were longer in
the BUMEL group of patients despite the fact that 19 patients
in the MEL200 group underwent a second ASCT. A prolonged
PFS with an equivalent CR/nCR rate posttransplantation has
also been reported in a recent update of results of the
GEM2000 trial (41 versus 31 months for patients treated
with oral BUMEL and MEL200, respectively; P ¼ .009)
[20], adding further evidence of the high antimyeloma
activity of the BUMEL combination as a preparative regimen
for ASCT. As in the previous PETHEMA/GEM2000 study, our
results also showed a longer PFS both when considering
patients achieving CR/nCR or less than nCR after trans-
plantation (data not shown). This ﬁnding could be because of
a better quality of response (more profound cytoreduction)
obtained with BUMEL than with MEL200. Unfortunately,Figure 2. Time to progression in BUMELonly conventional methods were used to evaluate response
after transplantation. Thus, further studies including more
sensitive methods to assess response are needed to conﬁrm
this hypothesis [26,29,30]. Finally, although formal compar-
isons are not possible between different studies, our results
show that duration of PFS achieved with BUMEL condi-
tioning regimen compares favorably with other series per-
forming single transplantation with MEL200 as the
preparative regimen (21-30.6 months) [3,6,31,32] and is
similar to trials including a double tandem transplantation
approach with MEL-only preparative regimens [33e35].
Diagnostic cytogenetic abnormalities in MM have been
associated with the outcome [36]. However, cytogenetic was
not a standard diagnostic procedure at the time when the
GEM2000 (control group) trial was launched and many
patients did not have this information available. Thus, we
could not match patients according to this important prog-
nostic factor.
Hematopoietic recovery was similar in both groups of
patients and within the limits expected in patients under-
going autografting with peripheral blood stem cells and the
procedure was well-tolerated with a low transplant-related
mortality. Mucositis was the most commonly reported
toxicity, it was more frequently observed among BUMEL
recipients, and it was associated with a longer duration of
hospitalization in this group of patients (21 versus 17 days).
Febrile neutropenia was more frequently observed among
those receiving BUMEL (84% versus 61%), although theregroup (d) and control group ($$$).
Figure 3. Overall survival in BUMEL group (d) and control group ($$$).
M. Blanes et al. / Biol Blood Marrow Transplant 19 (2013) 69e74 73were no differences in the incidence of microbiologically
documented infections between both groups. Seven of the 51
patients (14%) conditioned with BUMEL developed grade I/II
liver toxicity that did not require any speciﬁc therapy.
Interestingly, however, no patient developed hepatic SOS.
This ﬁnding, probably due to the absence of a ﬁrst-pass
hepatic effect of i.v. BU, supports our previous experience
[21] and that reported by other authors [37] as well as
conﬁrms the higher safety proﬁle of the i.v. formulation of BU
compared with the oral counterpart.
A conditioning regimen with bortezomib and MEL has
also been recently evaluated in patients with newly diag-
nosed MM undergoing ASCT with encouraging results [38].
Finally, our study was initiated before the introduction of
novel agent-based induction and a maintenance regimen.
Therefore, the prognostic impact of these factors has to be
further conﬁrmed in prospective studies, including new MM
agent-based induction treatments and posttransplantation
strategies of consolidation and/or maintenance [39].
In summary, although our study has limitations because
of its historical matched comparison, nonrandomized trial,
and small sample size of the BUMEL group, other study
characteristics, such as its prospective design, homogeneity
of inclusion criteria, and of induction regimens, as well as in
response to induction treatment, contribute positively to the
interest of this study. Our results suggest that single ASCT
conditionedwith i.v. BUMEL has a high antimyeloma activity,
and it is associated with a favorable trend in terms of PFS and
TTP when compared with a MEL-only transplantation.
Although MEL200 should still be considered the standard
condition regimen for ASCT in MM, based on our data and
data from literature, it is reasonable to design randomized
studies comparing MEL200 with i.v. BUMEL to optimize the
outcomes of ASCT in patients with MM as part of upfront
strategy therapy and to determine if i.v. BUMEL offers an
advantage over MEL200 alone.
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